Streetbeat News

BTCY

Biotricity, Inc.

https://www.biotricity.com

Industry

Medical - Devices

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

Open

0.35

Mkt cap

7.7M

Volume

450

High

0.35

P/E Ratio

-0.20

52-wk high

1.67

Low

0.34

Div yield

N/A

52-wk low

0.19

Biotricity Inc. announced its strategic expansion through a new partnership aimed at conducting cardiac screenings for patients with neurological issues. This move signifies the company's ongoing efforts to broaden its reach and capabilities in the healthcare sector.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 11:21 am

In Monday's intraday session, several healthcare stocks experienced significant movements. Fresh2 Group, Akso Health Group, ChromaDex, Elicio Therapeutics, Immuneering, and Biotricity saw their stock prices increase, with gains ranging from 21.08% to 41.7%. Conversely, Trxade Health, Envoy Medical, CareMax, Titan Pharma, Cargo Therapeutics, and Molecular Templates faced declines, with their stock prices dropping between 17.28% and 33%. CareMax's Q4 earnings were also released.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 5:31 pm

Biotricity Inc. (NASDAQ:BTCY) announced the expansion of its Cardiac AI Cloud platform, leveraging advancements in AI to improve operational efficiency and margins. The company is developing a cardiac AI clinical model to support clinical decisions, with plans to file for FDA clearance by year-end. The healthcare AI market is expected to reach $208.2 billion by 2030, with remote patient monitoring anticipated to hit $96.67 billion. Biotricity's expansion includes partnerships with Google's TensorFlow and Amazon Web Services, aiming to enhance diagnostic accuracy and patient outcomes through predictive analytics and the analysis of over 500 billion heartbeats.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 1:04 pm

Biotricity Inc. has received Health Canada clearance for its Biotres device, a significant regulatory approval that allows the company to market this device in Canada. This clearance is a crucial step for Biotricity, expanding its potential market and possibly impacting its revenue positively in the short term.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:26 pm

Biotricity (NASDAQ:BTCY) reported Q3 2024 adjusted EPS of $(0.12), surpassing the $(0.44) estimate, but its sales of $2.97M fell short of the $3.00M estimate. This represents a 20.90% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 11:14 pm

Fluor Corporation's shares fell by 7.7% following its Q4 results, with earnings beating estimates but sales missing expectations. Other stocks moved significantly in Tuesday's session, with notable gainers including TRxADE HEALTH, AgriFORCE Growing Systems, and Monopar Therapeutics, among others, due to various positive announcements. Losers included RAPT Therapeutics, MicroCloud Hologram, and Summit Therapeutics, primarily due to negative news or disappointing results.

Portfolio Pulse from Avi Kapoor

February 20, 2024 | 6:21 pm

Earnings reports for various companies are scheduled for February 20, 2024, with a mix of projected earnings and losses across different sectors. Notable companies include Walmart, Home Depot, Medtronic, and Barclays, among others, with expectations ranging from significant profits to losses per share.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 11:52 am

Biotricity (NASDAQ:BTCY) is scheduled to release its quarterly earnings report on February 20, 2024, with an expected EPS of $-0.44. Analysts and investors will be looking for the company to beat this estimate and provide positive guidance for the next quarter. Historical data shows mixed reactions in stock price to past earnings reports. Shares have declined 76.78% over the last 52 weeks, indicating potential concern among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 19, 2024 | 8:01 pm

Biotricity reports a preliminary Q3 2024 gross margin increase to 73% from 57% year-over-year, alongside a 30% reduction in operating expenses.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 1:10 pm

In Wednesday's pre-market session, health care stocks showed significant movement. Cogent Biosciences (COGT) led the gainers with a 45.6% increase, while Anitra (AZTR) experienced the largest decline, dropping 67.8%. Other notable movers include Lineage Cell Therapeutics (LCTX) and QuidelOrtho (QDEL), with QDEL's drop attributed to its Q4 earnings release.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 1:05 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.